Jason Coarse

956 total citations
47 papers, 691 citations indexed

About

Jason Coarse is a scholar working on Immunology, Rheumatology and Genetics. According to data from OpenAlex, Jason Coarse has authored 47 papers receiving a total of 691 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Immunology, 23 papers in Rheumatology and 22 papers in Genetics. Recurrent topics in Jason Coarse's work include Psoriasis: Treatment and Pathogenesis (22 papers), Spondyloarthritis Studies and Treatments (22 papers) and Inflammatory Bowel Disease (22 papers). Jason Coarse is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (22 papers), Spondyloarthritis Studies and Treatments (22 papers) and Inflammatory Bowel Disease (22 papers). Jason Coarse collaborates with scholars based in United States, United Kingdom and Germany. Jason Coarse's co-authors include Barbara Ink, Joseph F. Merola, Alice B. Gottlieb, Christopher T. Ritchlin, Iain B. McInnes, Richard B. Warren, Deepak Assudani, Laure Gossec, Laura C. Coates and Rajan Bajracharya and has published in prestigious journals such as The Lancet, Gastroenterology and Annals of the Rheumatic Diseases.

In The Last Decade

Jason Coarse

45 papers receiving 685 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jason Coarse United States	12	514	418	231	128	94	47	691
S. Mudivarthy Canada	3	489 1.0×	578 1.4×	363 1.6×	33 0.3×	48 0.5×	4	705
Dorothee Stichweh United States	5	287 0.6×	189 0.5×	118 0.5×	30 0.2×	68 0.7×	8	514
Jochen Sieper Germany	7	298 0.6×	545 1.3×	188 0.8×	30 0.2×	34 0.4×	8	694
Dafna Gladman Canada	4	455 0.9×	394 0.9×	221 1.0×	16 0.1×	33 0.4×	10	582
F. Heldmann Germany	15	557 1.1×	844 2.0×	293 1.3×	27 0.2×	23 0.2×	37	946
J. Eugene Huffstutter United States	10	111 0.2×	223 0.5×	109 0.5×	34 0.3×	62 0.7×	15	435
Mirjam K. de Vries Netherlands	8	212 0.4×	409 1.0×	108 0.5×	46 0.4×	21 0.2×	8	537
Olcay Aydıntuğ Türkiye	11	95 0.2×	231 0.6×	79 0.3×	89 0.7×	108 1.1×	20	426
Nathan den Broeder Netherlands	13	119 0.2×	228 0.5×	71 0.3×	94 0.7×	72 0.8×	59	430
Diahann T. S. L. Jansen Netherlands	13	190 0.4×	151 0.4×	53 0.2×	40 0.3×	70 0.7×	20	401

Countries citing papers authored by Jason Coarse

Since Specialization

Citations

This map shows the geographic impact of Jason Coarse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jason Coarse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jason Coarse more than expected).

Fields of papers citing papers by Jason Coarse

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jason Coarse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jason Coarse. The network helps show where Jason Coarse may publish in the future.

Co-authorship network of co-authors of Jason Coarse

This figure shows the co-authorship network connecting the top 25 collaborators of Jason Coarse. A scholar is included among the top collaborators of Jason Coarse based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jason Coarse. Jason Coarse is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gladman, Dafna, Philip J. Mease, Laure Gossec, et al.. (2025). Effect of Bimekizumab on Patient-Reported Outcomes and Work Productivity in Patients With Psoriatic Arthritis: 1-Year Results From 2 Phase III Studies. The Journal of Rheumatology. 52(5). 466–478.

Merola, Joseph F., Philip J. Mease, Atul Deodhar, et al.. (2024). P171 Bimekizumab impact on core group for research and assessment of psoriasis and psoriatic arthritis domains for patients with psoriatic arthritis: 52-week results from four phase 3 studies. Lara D. Veeken. 63(Supplement_1). 1 indexed citations

Mease, Philip J., Joseph F. Merola, Yoshiya Tanaka, et al.. (2024). Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies. Rheumatology and Therapy. 11(5). 1363–1382. 4 indexed citations

Coates, Laura C., Robert Landewé, Iain B. McInnes, et al.. (2024). Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL. RMD Open. 10(1). e003855–e003855. 18 indexed citations

Lichtenstein, Gary R., Scott D. Lee, Brian G. Feagan, et al.. (2024). Certolizumab Pegol Treatment in Patients With Crohn’s Disease: Final Safety Data From the SECURE Registry. Crohn s & Colitis 360. 7(1). otae083–otae083.

McInnes, Iain B., Philip J. Mease, Yoshiya Tanaka, et al.. (2023). POS1537 BIMEKIZUMAB EFFICACY AND SAFETY IN BIOLOGIC DMARD-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS WAS CONSISTENT WITH OR WITHOUT METHOTREXATE: 52-WEEK RESULTS FROM THE PHASE 3 ACTIVE‑REFERENCE STUDY BE OPTIMAL. Annals of the Rheumatic Diseases. 82. 1133–1134. 3 indexed citations

Ritchlin, Christopher T., Laura C. Coates, Iain B. McInnes, et al.. (2023). Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study. Annals of the Rheumatic Diseases. 82(11). 1404–1414. 30 indexed citations

Merola, Joseph F., Akihiko Asahina, Paolo Gisondi, et al.. (2023). 43744 Bimekizumab in bDMARD-naïve patients with psoriatic arthritis and skin involvement: Analysis of radiographic progression at Week 16 of BE OPTIMAL, a phase 3, multicenter, randomized, placebo- controlled, active reference study. Journal of the American Academy of Dermatology. 89(3). AB128–AB128. 1 indexed citations

Coates, Laura C., Iain B. McInnes, Joseph F. Merola, et al.. (2022). Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three‐Year Results From a Phase IIb Randomized Controlled Trial and Its Open‐Label Extension Study. Arthritis & Rheumatology. 74(12). 1959–1970. 27 indexed citations

10.

McInnes, Iain B., R. B. M. Landewé, Philip J. Mease, et al.. (2022). LB0001 BIMEKIZUMAB IN BDMARD-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS: 24-WEEK EFFICACY & SAFETY FROM BE OPTIMAL, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED, ACTIVE REFERENCE STUDY. Annals of the Rheumatic Diseases. 81. 206–207. 6 indexed citations

11.

McInnes, Iain B., Akihiko Asahina, Laura C. Coates, et al.. (2022). Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). The Lancet. 401(10370). 25–37. 95 indexed citations

12.

Merola, Joseph F., Robert Landewé, Iain B. McInnes, et al.. (2022). Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). The Lancet. 401(10370). 38–48. 104 indexed citations

13.

Heijde, Désirée van der, Lianne S. Gensler, Atul Deodhar, et al.. (2020). Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study. Annals of the Rheumatic Diseases. 79(5). 595–604. 97 indexed citations

14.

Ritchlin, Christopher T., Arthur Kavanaugh, Joseph F. Merola, et al.. (2020). Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. The Lancet. 395(10222). 427–440. 108 indexed citations

15.

Casteele, Niels Vande, Diane R. Mould, Jason Coarse, et al.. (2017). Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn’s Disease. Clinical Pharmacokinetics. 56(12). 1513–1523. 29 indexed citations

16.

Sandborn, William J., Douglas C. Wolf, Gordana Kosutic, et al.. (2017). Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol. Inflammatory Bowel Diseases. 23(7). 1047–1056. 20 indexed citations

17.

Lee, Scott D., David T. Rubin, William J. Sandborn, et al.. (2016). Reinduction with Certolizumab Pegol in Patients with Crohnʼs Disease Experiencing Disease Exacerbation. Inflammatory Bowel Diseases. 22(8). 1870–1880. 6 indexed citations

18.

Loftus, Edward V., Jean–Frédéric Colombel, Stefan Schreiber, et al.. (2015). Sa1139 Safety of Certolizumab Pegol in 2570 Crohn's Disease Patients With 4378 Patients Years at Risk: Integrated Data From the Global Clinical Program. Gastroenterology. 148(4). S–237. 1 indexed citations

19.

Arendt, Catherine, et al.. (2014). P-105 Dermatologic Complications in Patients Treated with Certolizumab Pegol. Inflammatory Bowel Diseases. 20. S70–S71. 1 indexed citations

20.

Ziegler, Bernhard, et al.. (1986). Adverse drug reaction reporting system: developing a well-monitored program.. PubMed. 21(9). 949–52. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact